Extensively drug-resistant tuberculosis: current challenges and threats

被引:97
作者
Jain, Amita [1 ]
Mondal, Rajesh [1 ]
机构
[1] CSM Med Univ, Dept Microbiol, Lucknow 226003, Uttar Pradesh, India
来源
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY | 2008年 / 53卷 / 02期
关键词
Mycobacterium tuberculosis; extensively drug-resistant tuberculosis;
D O I
10.1111/j.1574-695X.2008.00400.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Extensively drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis caused by a Mycobacterium tuberculosis strain that is resistant to at least rifampicin and isoniazid among the first-line antitubercular drugs (multidrug-resistant tuberculosis; MDR-TB) in addition to resistance to any fluroquinolones and at least one of three injectable second-line drugs, namely amikacin, kanamycin and/or capreomycin. Recent studies have described XDR-TB strains from all continents. Worldwide prevalence of XDR-TB is estimated to be c. 6.6% in all the studied countries among multidrug-resistant M. tuberculosis strains. The emergence of XDR-TB strains is a reflection of poor tuberculosis management, and controlling its emergence constitutes an urgent global health reality and a challenge to tuberculosis control activities in all parts of the world, especially in developing countries and those lacking resources and as well as in countries with increasing prevalence of HIV/AIDS.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 42 条
[1]  
[Anonymous], 2006, Weekly Epidemiological Record, V81, P430
[2]  
Bouvet Elisabeth, 2007, Rev Prat, V57, P1405
[3]   Does DOTS work in populations with drug-resistant tuberculosis? [J].
DeRiemer, K ;
García-García, L ;
Bobadilla-del-Valle, M ;
Palacios-Martínez, M ;
Martínez-Gamboa, A ;
Small, PM ;
Sifuentes-Osornio, J ;
Ponce-de-León, A .
LANCET, 2005, 365 (9466) :1239-1245
[4]   Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].
Dye, C ;
Scheele, S ;
Dolin, P ;
Pathania, V ;
Raviglione, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686
[5]   Standard short-course chemotherapy for drug-resistant tuberculosis -: Treatment outcomes in 6 countries [J].
Espinal, MA ;
Kim, SJ ;
Suarez, PG ;
Kam, KM ;
Khomenko, AG ;
Migliori, GB ;
Baéz, J ;
Kochi, A ;
Dye, C ;
Raviglione, MC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19) :2537-2545
[6]   Can DOTS control multidrug-resistant tuberculosis? [J].
Espinal, MA ;
Dye, C .
LANCET, 2005, 365 (9466) :1206-1209
[7]  
Farmer P, 1999, INT J TUBERC LUNG D, V3, P643
[8]   Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa [J].
Gandhi, Neel R. ;
Moll, Anthony ;
Sturm, A. Willem ;
Pawinski, Robert ;
Govender, Thiloshini ;
Lalloo, Umesh ;
Zeller, Kimberly ;
Andrews, Jason ;
Friedland, Gerald .
LANCET, 2006, 368 (9547) :1575-1580
[9]   Increasing transparency in partnerships for health - introducing the Green Light Committee [J].
Gupta, R ;
Cegielski, JP ;
Espinal, MA ;
Henkens, M ;
Kim, JY ;
Lambregts-van Weezenbeek, CSB ;
Lee, JW ;
Raviglione, MC ;
Suarez, PG ;
Varaine, F .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2002, 7 (11) :970-976
[10]  
Gupta R, 2001, INT J TUBERC LUNG D, V5, P1078